M. Hatada

发表

Catalytic metal ion binding in enolase: the crystal structure of an enolase-Mn2+-phosphonoacetohydroxamate complex at 2.4-A resolution.

E. Zhang, M. Hatada, J. Brewer, 1994, Biochemistry.

Catalytic metal ion binding in enolase: the crystal structure of an enolase-Mn2+-phosphonoacetohydroxamate complex at 2.4-A resolution.

E. Zhang, M. Hatada, J. Brewer, 1994 .

Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere.

M. Hatada, B. Graves, S. Redshaw, 1991, Journal of medicinal chemistry.

Crystal structure of the intensely sweet protein monellin

Sung-Hou Kim, M. Hatada, W. Shin, 1987, Nature.

Concepts and progress in the development of peptide mimetics.

M Kahn, M. Hatada, M. Bös, 1993, Journal of medicinal chemistry.

Discovery of GS-8374, a potent human immunodeficiency virus type 1 protease inhibitor with a superior resistance profile

William A. Lee, M. Hatada, M. Desai, 2011 .

Crystal and molecular structure of cofacial dicopper hexyldiporphyrin-7

M. Hatada, A. Tulinsky, C. Chang, 1980 .

Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.

William A. Lee, M. Hatada, Xiaohong Liu, 2006, Journal of molecular biology.

Structure-based design and synthesis of a novel class of Src SH2 inhibitors.

D. Holt, M. Hatada, R. Bohacek, 1999, Bioorganic & medicinal chemistry letters.

Selective epimerization of rapamycin via a retroaldol/aldol mechanism mediated by titanium tetraisopropoxide.

L. Rozamus, D. Holt, M. Hatada, 1999, Organic letters.

Crystal and molecular structure of cofacial dicopper hexyldiporphyrin-7

M. Hatada, A. Tulinsky, C. Chang, 1980 .

Bio–incorporation of telluromethionine into buried residues of dihydrofolate reductase

M. Hatada, L. Lebioda, R. B. Dunlap, 1994, Nature Structural Biology.

Structure of 2-keto-3-deoxy-6-phosphogluconate aldolase at 2 . 8 A resolution.

M. Hatada, L. Lebioda, A. Tulinsky, 1978, Journal of molecular biology.

Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.

Shannon R. Magari, L. Rozamus, D. Holt, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Microbial products. 9. Roxaticin, a new oxo pentaene antibiotic

M. Hatada, H. Maehr, Chaoqun Liu, 1989 .

Three-dimensional structure of thaumatin I, an intensely sweet protein.

S. Kim, M. Hatada, A. D. de Vos, 1985, Proceedings of the National Academy of Sciences of the United States of America.

A novel phosphotyrosine mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain.

C. Eyermann, M. Hatada, S. Violette, 2001, Bioorganic & medicinal chemistry letters.

Structure-based design of novel bicyclic nonpeptide inhibitors for the src SH2 domain.

M. Hatada, S. Violette, R. Bohacek, 2000, Journal of medicinal chemistry.

Solution structure of the C-terminal SH2 domain of the human tyrosine kinase Syk complexed with a phosphotyrosine pentapeptide.

M. Hatada, E. Laird, M. Botfield, 1995, Structure.

Comparison of the folding of 2-keto-3-deoxy-6-phosphogluconate aldolase, triosephosphate isomerase and pyruvate kinase. Implications in molecular evolution.

M. Hatada, L. Lebioda, A. Tulinsky, 1982, Journal of molecular biology.

A ligand-reversible dimerization system for controlling protein-protein interactions.

D N Woolfson, D. Holt, M. Hatada, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Expression, characterization and crystallographic analysis of telluromethionyl dihydrofolate reductase.

M. Hatada, L. Lebioda, R. B. Dunlap, 1995, Acta crystallographica. Section D, Biological crystallography.

Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity.

M. Hatada, S. Violette, R. Bohacek, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Identification of the discontinuous binding site in human interleukin 1 beta for the type I interleukin 1 receptor.

M. Hatada, B. Graves, V. Madison, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Structure of interleukin 1 alpha at 2.7-A resolution.

Y. Satow, M. Hatada, B. Graves, 1990, Biochemistry.

Structural comparisons among the short-chain helical cytokines.

A Wlodawer, A M Gronenborn, G M Clore, 1994, Structure.

Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor

Ellen R. Laird, M. Hatada, E. Laird, 2007, Nature.

CRYSTAL STRUCTURE OF ASPARTAME, A PEPTIDE SWEETENER

Sung-Hou Kim, M. Hatada, B. Graves, 1985 .

In Vitro Characterization of GS-8374, a Novel Phosphonate-Containing Inhibitor of HIV-1 Protease with a Favorable Resistance Profile

William A. Lee, M. Hatada, Xiaohong Liu, 2011, Antimicrobial Agents and Chemotherapy.

Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor

M. Hatada, E. Laird, M. Zoller, 1995, Nature.

X-Ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor.

M. Hatada, S. Violette, R. Bohacek, 2001, Journal of medicinal chemistry.

A ligand-reversible dimerization system for controlling protein-protein interactions.

M. Hatada, T. Clackson, D. Woolfson, 2000, Proceedings of the National Academy of Sciences of the United States of America.